On December 16, 2024, Andrew Dickinson, the Chief Financial Officer of Kite Pharma, a subsidiary of Gilead Sciences Inc (GILD, Financial), sold 8,500 shares of the company. Following this transaction, the insider now owns 132,373 shares of Gilead Sciences Inc. The details of this transaction can be found in the SEC Filing.
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company's primary areas of focus include antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, as well as treatments for cardiovascular, respiratory, and oncology diseases.
Over the past year, Andrew Dickinson has sold a total of 262,145 shares and has not purchased any shares. The insider transaction history for Gilead Sciences Inc indicates that there have been no insider buys in the past year, while there have been 16 insider sells.
On the day of the recent sale, shares of Gilead Sciences Inc were trading at $91.96, giving the stock a market cap of $114.968 billion. The company's price-earnings ratio stands at 1,025.00, which is higher than the industry median of 22.59 and also higher than the company's historical median price-earnings ratio.
With a trading price of $91.96 and a GF Value of $78.18, Gilead Sciences Inc has a price-to-GF-Value ratio of 1.18, indicating that the stock is modestly overvalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples, a GuruFocus adjustment factor, and future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
